cat no | io1013

ioGlutamatergic Neurons
PRKN R275W/WT™

Human iPSC-derived Parkinson's Disease model

ioGlutamatergic Neurons PRKN R275W/WT are opti‑ox™ precision reprogrammed glutamatergic neurons carrying a genetically engineered heterozygous mutation in the PRKN gene encoding the Parkin protein. These cells offer a rapidly maturing, disease relevant and isogenic system for investigating the molecular and cellular significance of a heterozygous R275W mutation in Parkinson’s disease.

Related disease model cells are coming soon with a homozygous PRKN R275W mutation, and both can be used alongside their genetically matched control, ioGlutamatergic Neurons™.

Coming Soon

Benchtop benefits

Make True Comparisons

Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to directly investigate the effect of heterozygous expression of mutant Parkin protein on disease.

Scalable

With opti-ox technology, we can make billions of consistently reprogrammed cells, surpassing the demands of industrial workflows.

Quick

The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.

Product information

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 48, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male (skin fibroblast)

Vial size

Small: >1 x 10⁶ viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)

Differentiation method

opti-ox cellular reprogramming

Recommended seeding density

30,000 cells/cm²

User storage

LN2 or -150°C

Format

Cryopreserved cells

Genetic modification

Heterozygous R275W missense mutation in the PRKN gene

Applications

Parkinson's disease research
Drug discovery and development
Disease modelling

Product use

ioCells are for research use only

Product resources

Poster

Development and characterisation of a robust in vitro disease model to study tauopathies

V1
2022
Charles River & bit.bio

Download

Poster

Validation of ALS-relevant phenotypes in precision reprogrammed iPSC-derived glutamatergic Neurons containing a TDP-43 M337V mutation.

V1
2022
Charles River & bit.bio

Download

Video

Partnering with Charles River to advance CNS drug discovery with ioGlutamatergic Neurons™

Charles River

Watch now

Video tutorial

Culturing Glutamatergic Neurons | How-to Video

Dr Kaiser Karim | Scientist
bit.bio

Watch now

Video tutorial

Preparing Culture Vessels for Glutamatergic Neurons | How-to Video

Dr Kaiser Karim | Scientist
bit.bio

Watch now

Video

In Conversation with Charles River

Dr Marijn Vlaming | Head of Biology
Charles River

Watch now

Poster

High Content Analysis of 2D and 3D cellular models for target and phenotypic drug discovery

Lachize | et al
Courtesy of Charles River Laboratories

Download

Addressing current challenges of in vitro cell models

Read this blog to find out how experts from across academia and industry are approaching the challenges of reproducibility of in vitro cell models as well as potential solutions.

Read the blog